Sizing SGLT2 Inhibitors Up: From a Molecular to a Morpho-Functional Point of View
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241813848 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Silvia Prosperi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, It…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Sodium–glucose cotransporter 2 inhibitors (SGLT2i), or gliflozins, have recently been shown to reduce cardiovascular death and hospitalization in patients with heart failure, representing a revolutionary therapeutic tool. The purpose of this review is to explore their multifaceted mechanisms of actions, beyond their known glucose reduction power. The cardioprotective effects of gliflozins seem to be linked to the maintenance of cellular homeostasis and to an action on the main metabolic pathways. They improve the oxygen supply for cardiomyocytes with a considerable impact on both functional and morphological myocardial aspects. Moreover, multiple molecular actions of SGLT2i are being discovered, such as the reduction of both inflammation, oxidative stress and cellular apoptosis, all responsible for myocardial damage. Various studies showed controversial results concerning the role of SGLT2i in reverse cardiac remodeling and the lowering of natriuretic peptides, suggesting that their overall effect has yet to be fully understood. In addition to this, advanced imaging studies evaluating the effect on all four cardiac chambers are lacking. Further studies will be needed to better understand the real impact of their administration, their use in daily practice and how they can contribute to benefits in terms of reverse cardiac remodeling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy.
ORCID-Profile: Paolo Severino, Roberto Badagliacca, Viviana Maestrini, Carmine Dario Vizza
Zitieren
APA
Prosperi, S., D'Amato, A., Severino, P., Myftari, V., Monosilio, S., Marchiori, L., Zagordi, L. M., Filomena, D., Di Pietro, G., Birtolo, L. I., Badagliacca, R., Mancone, M., Maestrini, V., & Vizza, C. D. (2023). Sizing SGLT2 Inhibitors Up: From a Molecular to a Morpho-Functional Point of View. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241813848
Vancouver
Prosperi S, D'Amato A, Severino P, Myftari V, Monosilio S, Marchiori L, et al. Sizing SGLT2 Inhibitors Up: From a Molecular to a Morpho-Functional Point of View. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241813848
BibTeX
@article{Prosperi2023,
author = {Prosperi, Silvia and D'Amato, Andrea and Severino, Paolo and Myftari, Vincenzo and Monosilio, Sara and Marchiori, Ludovica and Zagordi, Lucrezia Maria and Filomena, Domenico and Di Pietro, Gianluca and Birtolo, Lucia Ilaria and Badagliacca, Roberto and Mancone, Massimo and Maestrini, Viviana and Vizza, Carmine Dario},
title = {Sizing SGLT2 Inhibitors Up: From a Molecular to a Morpho-Functional Point of View},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241813848}
}
EUVIMED